187 related articles for article (PubMed ID: 16406098)
41. In vitro and in vivo characterization of equine herpesvirus type 1 (EHV-1) mutants devoid of the viral chemokine-binding glycoprotein G (gG).
von Einem J; Smith PM; Van de Walle GR; O'Callaghan DJ; Osterrieder N
Virology; 2007 May; 362(1):151-62. PubMed ID: 17250864
[TBL] [Abstract][Full Text] [Related]
42. Functional analysis of vaccinia virus B5R protein: essential role in virus envelopment is independent of a large portion of the extracellular domain.
Herrera E; Lorenzo MM; Blasco R; Isaacs SN
J Virol; 1998 Jan; 72(1):294-302. PubMed ID: 9420227
[TBL] [Abstract][Full Text] [Related]
43. Mapping and functional analysis of interaction sites within the cytoplasmic domains of the vaccinia virus A33R and A36R envelope proteins.
Ward BM; Weisberg AS; Moss B
J Virol; 2003 Apr; 77(7):4113-26. PubMed ID: 12634370
[TBL] [Abstract][Full Text] [Related]
44. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
[TBL] [Abstract][Full Text] [Related]
45. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
46. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
47. Lung surfactant DPPG phospholipid inhibits vaccinia virus infection.
Perino J; Crouzier D; Spehner D; Debouzy JC; Garin D; Crance JM; Favier AL
Antiviral Res; 2011 Jan; 89(1):89-97. PubMed ID: 21095206
[TBL] [Abstract][Full Text] [Related]
48. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.
Dénes B; Gridley DS; Fodor N; Takátsy Z; Timiryasova TM; Fodor I
J Gene Med; 2006 Jul; 8(7):814-23. PubMed ID: 16634110
[TBL] [Abstract][Full Text] [Related]
49. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination.
Wolffe EJ; Isaacs SN; Moss B
J Virol; 1993 Aug; 67(8):4732-41. PubMed ID: 8331727
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity, pathogenicity, and transmissibility of a recombinant vaccinia virus in calves.
Wedman EE; Smith AW; Oliver RE
Am J Vet Res; 1988 Dec; 49(12):2018-21. PubMed ID: 3239835
[TBL] [Abstract][Full Text] [Related]
51. Immunization of rabbits with a modified vaccinia Ankara recombinant virus bearing the HIV envelope antigen on its outer membrane.
Barchichat S; Katz E
Virus Res; 2002 Dec; 90(1-2):243-51. PubMed ID: 12457978
[TBL] [Abstract][Full Text] [Related]
52. Phenotypic and genetic diversity of the traditional Lister smallpox vaccine.
Garcel A; Perino J; Crance JM; Drillien R; Garin D; Favier AL
Vaccine; 2009 Jan; 27(5):708-17. PubMed ID: 19059294
[TBL] [Abstract][Full Text] [Related]
53. Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
Weyer J; Rupprecht CE; Mans J; Viljoen GJ; Nel LH
Vaccine; 2007 May; 25(21):4213-22. PubMed ID: 17434244
[TBL] [Abstract][Full Text] [Related]
54. The effects of targeting the vaccinia virus B5R protein to the endoplasmic reticulum on virus morphogenesis and dissemination.
Mathew EC; Sanderson CM; Hollinshead R; Hollinshead M; Grimley R; Smith GL
Virology; 1999 Dec; 265(1):131-46. PubMed ID: 10603324
[TBL] [Abstract][Full Text] [Related]
55. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.
Dupuy LC; Locher CP; Paidhungat M; Richards MJ; Lind CM; Bakken R; Parker MD; Whalen RG; Schmaljohn CS
Vaccine; 2009 Jun; 27(31):4152-60. PubMed ID: 19406186
[TBL] [Abstract][Full Text] [Related]
56. Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes.
Tscharke DC; Reading PC; Smith GL
J Gen Virol; 2002 Aug; 83(Pt 8):1977-1986. PubMed ID: 12124461
[TBL] [Abstract][Full Text] [Related]
57. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus.
Roper RL; Wolffe EJ; Weisberg A; Moss B
J Virol; 1998 May; 72(5):4192-204. PubMed ID: 9557708
[TBL] [Abstract][Full Text] [Related]
58. Role for the vaccinia virus A36R outer envelope protein in the formation of virus-tipped actin-containing microvilli and cell-to-cell virus spread.
Wolffe EJ; Weisberg AS; Moss B
Virology; 1998 Apr; 244(1):20-6. PubMed ID: 9581774
[TBL] [Abstract][Full Text] [Related]
59. A highly attenuated rabies virus HEP-Flury strain reverts to virulent by single amino acid substitution to arginine at position 333 in glycoprotein.
Takayama-Ito M; Inoue K; Shoji Y; Inoue S; Iijima T; Sakai T; Kurane I; Morimoto K
Virus Res; 2006 Aug; 119(2):208-15. PubMed ID: 16473429
[TBL] [Abstract][Full Text] [Related]
60. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread.
Luker KE; Hutchens M; Schultz T; Pekosz A; Luker GD
Virology; 2005 Oct; 341(2):284-300. PubMed ID: 16095645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
